Loading...
OX40-enhanced tumor rejection and effector T cell differentiation decreases with age
OX40 agonists have potent immunotherapeutic effects against a variety of murine tumors, yet it is unclear the role that age-related immune senescence plays on their efficacy. We found that middle-aged and elderly tumor-bearing mice (12 and 20 months old, respectively) treated with anti-OX40 were les...
Saved in:
| Published in: | J Immunol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2009
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6760259/ https://ncbi.nlm.nih.gov/pubmed/19155495 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.182.3.1481 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|